Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
批准号:
7770636
负责人:
Melissa Caroline Skala
金额:
$8.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-28 至 2010-06-30
关键词:
AddressAlzheimer&aposs DiseaseAngiogenesis InhibitorsAnimalsBiological MarkersBloodBlood VesselsBlood flowBreast Cancer CellBreast Cancer TreatmentCaringCellsClinicalClinical TrialsCombined Modality TherapyDataDisciplineDiseaseDorsalDoseDrug FormulationsDrug resistanceERBB2 geneEnvironmentFutureGoldGrowthHER2 inhibitionHeatingHumanHypoxiaImageImaging TechniquesKineticsKnowledgeLasersMalignant NeoplasmsMeasurementMentorshipMethodsMicroscopeMicroscopyMolecularMonitorMorbidity - disease rateMorphologyMusOptical Coherence TomographyPatientsPenetrationPharmaceutical PreparationsPharmacodynamicsPhasePre-Clinical ModelPreclinical Drug EvaluationReceptor CellReceptor InhibitionReceptor Protein-Tyrosine KinasesRelative (related person)ResistanceResolutionScheduleSignal TransductionSignaling ProteinSkinSpecificityStructureTechniquesTechnologyTestingTherapeuticTimeTissuesTopical applicationTranslatingTrastuzumabTumor AngiogenesisUniversitiesVariantWorkabstractingangiogenesisbevacizumabcancer therapycellular imagingdesignhemodynamicshumanized antibodyimaging modalityimprovedin vivomolecular imagingmortalitynanoparticlenoveloptical imagingpre-clinicalpublic health relevancereceptor expressionrelating to nervous systemresponsesuccesstherapeutic targettooltreatment effecttreatment strategytumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Abstract Molecular signaling is a critical therapeutic target in cancer, and molecular therapeutics have achieved some success in treating a variety of cancers. However, our incomplete knowledge of pharmacodynamic effects in vivo limits the success of these molecular therapies. We have recently developed a new molecular imaging technique, photothermal optical coherence tomography (OCT) that extends the penetration depth of high resolution molecular imaging beyond the microscopy limit. The current proposal will further develop photothermal OCT for in vivo imaging of cell receptors, and will combine this new technique with the high resolution hemodynamic imaging capabilities of Doppler OCT and hyperspectral imaging to provide a comprehensive picture of the pharmacodynamic effects of molecular cancer therapies in human cells grown into tumors in the mouse window chamber. The first aim will use a combined hyperspectral / OCT microscope to quantify changes in blood oxygenation, and three dimensional blood flow and microvessel morphology with tumor growth and with antiangiogenic treatment. The second aim will develop photothermal OCT for in vivo imaging of cell receptors, and will quantify the pharmocodynamics of receptor inhibition in the mouse window chamber. The final aim will combine photothermal OCT and hyperspectral / Doppler OCT to quantify longitudinal changes in both receptor expression and hemodyanmic response to combined receptor inhibition and antiangiogenic therapies in mouse window chamber tumors. These studies will establish our novel hemodynamic (Doppler OCT and hyperspectral imaging) and molecular (photothermal OCT) imaging techniques as high resolution, three-dimensional drug screening methods for preclinical applications. This work will be conducted under the co-mentorship of Drs. Mark Dewhirst and Joseph Izatt, who are experts in the fields of tumor therapy and optical imaging, respectfully, at Duke University. This multi-disciplinary environment will provide an excellent opportunity for professional growth and scientific advancement.
PUBLIC HEALTH RELEVANCE: This work will develop imaging methods to study the hemodynamic and molecular response to drugs in preclinical models, allowing for the formulation of rational dosing and scheduling strategies that maximize the effect of these drugs. The optical imaging approach developed in this proposal is attractive because it provides a unique set of multi-functional information that is difficult to obtain with other techniques; it is cheap and readily applied across a broad range of disciplines. In the future, similar technologies could be translated to clinical use to provide individualized care to patients with a variety of diseases including cancer, Alzheimer's, and neural diseases, thus decreasing morbidity and mortality.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging
-
批准号:10550200
-
项目类别:
-
资助金额:$24.8万
-
财政年份:2022
-
负责人:Melissa Caroline Skala
-
依托单位:
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging
-
批准号:10380391
-
项目类别:
-
资助金额:$23.22万
-
财政年份:2022
-
负责人:Melissa Caroline Skala
-
依托单位:
Optical imaging of pancreas cancer organoids for drug development and personalized treatment
-
批准号:9388210
-
项目类别:
-
资助金额:$64.84万
-
财政年份:2017
-
负责人:Melissa Caroline Skala
-
依托单位:
Optical imaging of pancreas cancer organoids for drug development and personalized treatment
-
批准号:10223218
-
项目类别:
-
资助金额:$55.49万
-
财政年份:2017
-
负责人:Melissa Caroline Skala
-
依托单位:
Optical imaging of pancreas cancer organoids for drug development and personalized treatment
-
批准号:9769226
-
项目类别:
-
资助金额:$24.64万
-
财政年份:2017
-
负责人:Melissa Caroline Skala
-
依托单位:
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
-
批准号:9323359
-
项目类别:
-
资助金额:$38.84万
-
财政年份:2016
-
负责人:Melissa Caroline Skala
-
依托单位:
Cellular level optical metabolic imaging to predict drug response in cancer
-
批准号:9298127
-
项目类别:
-
资助金额:$31.54万
-
财政年份:2014
-
负责人:Melissa Caroline Skala
-
依托单位:
Cellular level optical metabolic imaging to predict drug response in cancer
-
批准号:9767107
-
项目类别:
-
资助金额:$30.53万
-
财政年份:2014
-
负责人:Melissa Caroline Skala
-
依托单位:
Cellular level optical metabolic imaging to predict drug response in cancer
-
批准号:9138626
-
项目类别:
-
资助金额:$31.47万
-
财政年份:2014
-
负责人:Melissa Caroline Skala
-
依托单位:
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
-
批准号:8128195
-
项目类别:
-
资助金额:$24.75万
-
财政年份:2010
-
负责人:Melissa Caroline Skala
-
依托单位:
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
-
批准号:8307913
-
项目类别:
-
资助金额:$23.95万
-
财政年份:2010
-
负责人:Melissa Caroline Skala
-
依托单位:
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
-
批准号:8137980
-
项目类别:
-
资助金额:$24.03万
-
财政年份:2010
-
负责人:Melissa Caroline Skala
-
依托单位:
Molecular optical coherence tomography for monitoring cancer therapy
-
批准号:7331664
-
项目类别:
-
资助金额:$4.48万
-
财政年份:2007
-
负责人:Melissa Caroline Skala
-
依托单位:
Molecular optical coherence tomography for monitoring cancer therapy
-
批准号:7637468
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2007
-
负责人:Melissa Caroline Skala
-
依托单位:
Molecular optical coherence tomography for monitoring cancer therapy
-
批准号:7454210
-
项目类别:
-
资助金额:$4.68万
-
财政年份:2007
-
负责人:Melissa Caroline Skala
-
依托单位: